Small Molecule

Pipeline

Advancing a proprietary pipeline of innovative molecular therapies

We are committed to progressing a portfolio of first-in-class, disease-modifying therapeutics to provide new treatment options for patients.

Neurodon has identified specific cellular stress pathways that are responsible for the progression of such diverse conditions as neurodegenerative disease, diabetes, autoimmune disease, ischemia, and stroke. We have recognized the importance of this pathological mechanism and are committed to developing safe and effective molecular therapies addressing this feature.

Targeted
Disease
Cellular
Discovery
Lead
Optimization
IND
Enabling
Phase
One
Phase
Two
Phase
Three
Diabetes
Type 1 & 2

Our diabetes lead candidate NDC-0009 has shown efficacy as a disease modifying treatment in several animal and human models of both Type 1 and Type 2 Diabetes. In addition to regulating glucose and improving insulin secretion and response, this molecule also protects pancreatic beta cells in human tissues. We have initiated required IND-enabling studies with plans to submit the application to the FDA within the next 8-12 months.

Alzheimer’s
Disease

Neurodon’s Alzheimer’s program is currently in late lead optimization status with several potential development candidates identified. In collaboration with the National Institute on Aging of the NIH, we are currently performing several pivotal efficacy and safety studies to prioritize our lead candidates.

Parkinson’s
Disease

We have identified several orally-available molecules that show compelling efficacy in animal models of Parkinson’s disease. These candidates are currently undergoing lead optimization with the goal of selecting development candidates later this year.

Rare, Orphan
Diseases

In collaboration with our academic colleagues, we have identified molecules that show efficacy in diverse rare diseases such as Huntington’s disease, muscular dystrophy, and other indications. These molecules are in various stages of development with the potential for rapid acceleration to clinical status due to their orphan status.

Curing the Incurable logo

Collaborate with Neurodon

Let’s research new candidates with novel targets.

CONTACT US
CONTACT